315 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Kelly
    Kelly
  4. Gerecitano
    Gerecitano
  5. O'Reilly
    O'Reilly
  6. Slovin
    Slovin
  7. Smart-Curley
    Smart-Curley
  8. Morris
    Morris
  9. Schwartz
    Schwartz
  10. Zelenetz
    Zelenetz

Groups

  1. Department of Medicine (223)
  2. Solid Tumor Oncology Division (164)
  3. Hematologic Malignancies, Division of (77)
  4. Genitourinary Oncology Service (67)
  5. Center for Hematologic Malignancies (53)
  6. Epidemiology and Biostatistics (47)
  7. Biostatistics Service (45)
  8. Survivorship Research (45)
  9. Radiology, Department of (42)
  10. Nursing (41)
  1. "hyperglycemia"
Formats
  1. Journal Article (294)
  2. Review (17)
  3. Guidelines (2)
  4. Correspondence (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (223)
  2. Solid Tumor Oncology Division (164)
  3. Hematologic Malignancies, Division of (77)
  4. Genitourinary Oncology Service (67)
  5. Center for Hematologic Malignancies (53)
  6. Epidemiology and Biostatistics (47)

More Groups

People
  1. Robert Motzer (28)
  2. Howard Scher (15)
  3. William Kelly (14)
  4. Eileen O'Reilly (11)
  5. John Gerecitano (11)
  6. Susan Slovin (11)

More People

Years
  1. 2025 (8)
  2. 2024 (20)
  3. 2023 (20)
  4. 2022 (15)
  5. 2021 (9)
  6. 2020 (22)

More Years

Publications
  1. Journal of Clinical Oncology (27)
  2. Clinical Cancer Research (20)
  3. Cancer (14)
  4. Lancet Oncology (14)
  5. Annals of Oncology (12)
  6. Investigational New Drugs (12)

More Publications

Publishers
  1. Elsevier Inc. (42)
  2. Springer (32)
  3. American Society of Clinical Oncology (28)
  4. Elsevier Science, Inc. (23)
  5. Oxford University Press (23)
  6. American Association for Cancer Research (21)

More Publishers

Results (315)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
    Journal Article

    Noel, M.; O’Reilly, E. M.; Wolpin, B. M.; Ryan, D. P.; Bullock, A. J.; Britten, C. D.; Linehan, D. C.; Belt, B. A.; Gamelin, E. C.; Ganguly, B.; more...
    Investigational New Drugs (2020)

    Fulltext@MSK | Save
  • Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer
    Review

    Drullinsky, P. R.; Hurvitz, S. A.
    Breast Cancer Research and Treatment (2020)

    Fulltext@MSK | Save
  • Selinexor: A first-in-class nuclear export inhibitor for management of multiply relapsed multiple myeloma
    Review

    Peterson, T. J.; Orozco, J.; Buege, M.
    Annals of Pharmacotherapy (2020)

    Fulltext@MSK | Save
  • A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)
    Journal Article

    Lancet, J. E.; Moseley, A. B.; Coutre, S. E.; DeAngelo, D. J.; Othus, M.; Tallman, M. S.; Litzow, M. R.; Komrokji, R. S.; Erba, H. P.; Appelbaum, F. R.
    Blood Advances (2020)

    Fulltext@MSK | Save
  • A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease
    Journal Article

    Schroeder, M. A.; Jean Khoury, H.; Jagasia, M.; Ali, H.; Schiller, G. J.; Staser, K.; Choi, J.; Gehrs, L.; Arbushites, M. C.; Yan, Y.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia
    Journal Article

    Shah, N. N.; Bhojwani, D.; August, K.; Baruchel, A.; Bertrand, Y.; Boklan, J.; Dalla-Pozza, L.; Dennis, R.; Hijiya, N.; Locatelli, F.; more...
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer
    Journal Article

    Cadoo, K. A.; Grisham, R. N.; O'Cearbhaill, R. E.; Boucicaut, N. N.; Henson, M.; Iasonos, A.; Zhou, Q.; Sarasohn, D. M.; Gallagher, J.; Kravetz, S.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Renal toxicity of systemic therapy for renal cell carcinoma
    Review

    Jaimes, E. A.
    Seminars in Nephrology (2020)

    Fulltext@MSK | Save
  • Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
    Journal Article

    Rubinstein, M. M.; Hyman, D. M.; Caird, I.; Won, H.; Soldan, K.; Seier, K.; Iasonos, A.; Tew, W. P.; O’Cearbhaill, R. E.; Grisham, R. N.; more...
    Cancer (2020)

    Fulltext@MSK | Save